Tenecteplase is under clinical development by Shimao Tianjie Pharmaceutical (Jiangsu) and currently in Phase II for Pulmonary Embolism. According to GlobalData, Phase II drugs for Pulmonary Embolism have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tenecteplase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tenecteplase overview

Tenecteplase (Tianlitong) is a recombinant tissue plasminogen activator. It is formulated as powder for solution for intravenous route of administration. Tianlitong is indicated in the thrombolytic treatment of acute ST-segment elevation myocardial infarction.
Tenecteplase is under development for the treatment of acute ischemic stroke and acute pulmonary embolism. It is administered by intravenous route as powder for solution. It is a recombinant human tissue plasminogen activator.

For a complete picture of Tenecteplase’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.